Targeted therapy at the end of life in advanced cancer patients

Journal of Palliative Medicine

Volumn 15, Issue 9, 2012, Pages 991-997

  Soh, Thomas I Peng ^a   Yuen, Yi Ching ^a   Teo, Catherine ^a   Lim, Siew Woon ^a   Chan, Noreen ^a   Wong, Alvin Seng Cheong ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL DECISION MAKING; COLORECTAL CANCER; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SOLID TUMOR; SYSTEMIC THERAPY; TERMINAL CARE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; CANCER CARE FACILITIES; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; PALLIATIVE CARE; RETROSPECTIVE STUDIES; SINGAPORE; TERMINALLY ILL; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84866163546     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2012.0050     Document Type: Article

References (41)

1. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-242. (Pubitemid 34438862)
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-1672. (Pubitemid 41464705)
3. Ho TH, Barbera L, Saskin R, Lu H, Neville BA, Earle CC: Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol 2011;29(12):1587-1591.
4. Wong AS, Teo C, Lim SW, Wong E, Soo RA, Chan N: Targeted therapy at the end of life for patients with lung cancer. J Palliat Med 2010;13(8):945-948.
5. Sledge GW, Jr.: What is targeted therapy? J Clin Oncol 2005;23(8):1614-1615. (Pubitemid 46211413)
6. National Registry of Diseases Office (NRDO) of Singapore. www.nrdo.gov.sg/uploadedFiles/NRDO/Cancer-Trends-Report%20-05-09.pdf. (Last accessed January 26, 2012).
7. Hong CY, Chow KY, Poulose J, et al.: Place of death and its determinants for patients with cancer in singapore: An analysis of data from the Singapore cancer registry, 2000.J Palliat Med 2011;14(10):1128-1134.
8. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ: Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol 2008;26(23): 3860-3866.
9. Braga S, Miranda A, Fonseca R, et al.: The aggressiveness of cancer care in the last three months of life: A retrospective single centre analysis. Psychooncology 2007;16(9):863-868. (Pubitemid 47456246)
10. Yun YH, Kwak M, Park SM, et al.: Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 2007;72(3-4):164-171. (Pubitemid 351161605)
11. Nappa U, Lindqvist O, Rasmussen BH, Axelsson B: Palliative chemotherapy during the last month of life. Ann Oncol 2011;22(11):2375-2380.
12. Weinstein IB: Cancer: Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297(5578):63-64. (Pubitemid 34743088)
13. Wong AS, Soong R, Seah SB, et al.: Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008;3(4):400-404. (Pubitemid 351489481)
14. Wong AS, Seto KY, Chin TM, Soo RA: Lung cancer response to gefitinib, then erlotinib, then gefitinib again. J Thorac Oncol 2008;3(9):1077-1078.
15. Watanabe S, Tanaka J, Ota T, et al.: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: A retrospective analysis. BMC Cancer 2011; 11:1.
16. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(15):1960-1966. (Pubitemid 46972777)
17. Van Cutsem E, Kohne CH, Lang I, et al.: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29(15):2011-2019.
18. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-480. (Pubitemid 34879334)
19. Inoue A, Kobayashi K, Usui K, et al.: First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27(9):1394-1400.
20. Langer CJ: "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol 2009;27(9):1350-1354.
21. Maemondo M, Inoue A, Kobayashi K, et al.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362(25):2380- 2388.
22. Mitsudomi T, Morita S, Yatabe Y, et al.: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11(2):121-128.
23. Motzer RJ, Hutson TE, Tomczak P, et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-3590.
24. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4): 378-390.
25. Miles DW, Chan A, Dirix LY, et al.: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28(20):3239-3247.
26. Miller K, Wang M, Gralow J, et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666- 2676.
27. Robert NJ, Dieras V, Glaspy J, et al.: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(10):1252-1260.
28. Vermorken JB, Mesia R, Rivera F, et al.: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-1127.
29. Braga S: Why do our patients get chemotherapy until the end of life? Ann Oncol 2011;22(11):2345-2348.
30. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-2516.
31. Choi YL, Soda M, Yamashita Y, et al.: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2011;363(18):1734-1739.
32. Chabner BA: Early accelerated approval for highly targeted cancer drugs. N Engl J Med 2011;364(12):1087-1089.
33. Sleijfer S, Verweij J: The price of success: Cost-effectiveness of molecularly targeted agents. Clin Pharmacol Ther 2009; 85(2):136-138.
34. Fishman J, Ten Have T, Casarett D: Cancer and the media: How does the news report on treatment and outcomes? Arch Intern Med 2010;170(6):515-518.
35. Seruga B, Sterling L, Wang L, Tannock IF: Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 2011;29(2): 174-185.
36. Ocana A, Tannock IF: When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst 2011;103(1):16-20.
37. Harrington SE, Smith TJ: The role of chemotherapy at the end of life: "When is enough, enough?" JAMA 2008;299(22): 2667-2678. (Pubitemid 351831596)
38. Saito AM, Landrum MB, Neville BA, Ayanian JZ, Earle CC: The effect on survival of continuing chemotherapy to near death. BMC Palliat Care 2011;10:14.
39. Wong AS: Reviewer's report: The effect on survival of continuing chemotherapy to near death. 2010. www.biomedcentral .com/1472-684X/10/14/prepub (last accessed 1/26/2012).
40. Earle CC, Ayanian JZ: Looking back from death: The value of retrospective studies of end-of-life care. J Clin Oncol 2006;24(6):838-840. (Pubitemid 46638831)
41. Matsuyama R, Reddy S, Smith TJ: Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 2006;24(21):3490-3496. (Pubitemid 46638908)